Authors: Eric M. Jurgens, Ross S. Firestone, Jagrutiben Chaudhari, Kinga Hosszu, Sean M. Devlin, Urvi A. Shah, Jonathan Landa, Devin P. McAvoy, Alexander M. Lesokhin, Neha Korde, Hani Hassoun, Carlyn R. Tan, Malin Hultcrantz, Gunjan L. Shah, Heather J. Landau, David J. Chung, Michael Scordo, Ozgur Can Eren, Ahmet Dogan, Sergio A. Giralt, Jae H. Park, Isabelle Rivière, Renier J. Brentjens, Eric L. Smith, Xiuyan Wang, Saad Z. Usmani, Sham Mailankody
Published: 2024-12-04
DOI: 10.1200/jco-24-01785
Source: Full article
MCARH109 is a first-in-class G protein–coupled receptor, class C, group 5, member D (GPRC5D)-targeted chimeric antigen receptor (CAR) T-cell therapy for patients with relapsed/refractory multiple myeloma. This phase I clinical trial included 17 patients and determined that MCARH109 is safe at a maximum tolerated dose of 150 × 10